PFIZER - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 2.8
Show all parameters (20 more)
🏭 Industry
The pharmaceutical industry typically exhibits high capital expenditure and regulatory hurdles, leading to varying margins and a degree of cyclicality in demand. Innovation and patent protection are crucial for sustained profitability; companies with strong pipelines and established brands often command premium valuations.
✅ Positive
Pfizer demonstrates consistent profitability with a 6.63% quarter-on-quarter profit increase, underpinned by a healthy PAT of 204 Cr. The debt-to-equity ratio of 0.02 indicates a remarkably conservative capital structure and strong financial stability.
⚠️ Limitation
Despite the positive profit growth, the stock trades at a premium valuation relative to its industry, indicated by a P/E ratio of 24.2 compared to the industry average of 34.6. The RSI of 18.4 suggests that the stock is currently undervalued relative to its historical levels, however, this could represent an overreaction driven by recent negative news and a potentially temporary market correction.
📉 Company Negative News
Recent news highlights a significant price decline, pushing Pfizer to a 52-week low of Rs 4,054.55. This downward pressure is amplified by broader market sentiment surrounding Novartis's performance, indicating potential headwinds impacting the pharmaceutical sector.
🧾 Long-Term Outlook
Entry Zone: 4,150 - 4,250 ₹ – Given the current price near the low and a relatively conservative valuation relative to its earnings potential, this range represents an opportune entry point. Holding Guidance: Maintain a long-term holding perspective, focusing on Pfizer’s established product portfolio and R&D investment. A key metric to watch is the trajectory of new drug approvals and their impact on revenue growth – expect volatility in the short term but look for consistent profitability to drive shareholder value over the longer horizon. Final Verdict: Cautiously optimistic; the stock's strong financial health, coupled with its competitive advantages, supports a positive outlook despite current market anxieties.